sur MEDIAN TECHNOLOGIES (EPA:ALMDT)
Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024
Median Technologies has announced its participation in the RSNA 2024 Annual Meeting in Chicago. The event will be held from December 1-5. The company will demonstrate their AI-powered diagnostic software, eyonis™ LCS, designed to enhance early lung cancer screening. Located at booth #5442, Median's teams will present their latest advancements.
A peer-reviewed scientific e-poster and an AI Theater presentation are among the highlights. These sessions will explore the capabilities of eyonis™ LCS in comparison to radiologists, and its potential to boost global lung cancer screening programs. Earlier this year, eyonis™ LCS met significant milestone endpoints in its REALITY clinical trial.
The company plans to file for marketing authorization in the US and Europe by the first half of 2025, following results from a second pivotal study. Median Technologies aims to establish their diagnostic device as a critical tool in the fight against lung cancer.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de MEDIAN TECHNOLOGIES